Forest Labs, Gedeon Reports Phase III Results From Trial Of Cariprazine - NASDAQ

Forest Labs, Gedeon Reports Phase III Results From Trial Of Cariprazine NASDAQ Cariprazine is also currently being investigated in clinical studies for patients with schizophrenia, bipolar depression, and as an adjunct treatment for Major Depressive Disorder. Zsolt Szombathelyi, MD, Research Director of Gedeon Richter, said, ... Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase III ...MarketWatch (press release) all 10 news articles »

Race and mental illness: Do African Americans suffer more schizophrenia or is ... - Los Angeles Times

Race and mental illness: Do African Americans suffer more schizophrenia or is ... Los Angeles Times But sometimes those same symptoms point to extreme cases of depression or bipolar disorder. Before assigning a diagnosis of schizophrenia, a physician is expected to rule out these more treatable conditions. The new study found that in a group of 610 ... and more »